Phase I Clinical and Pharmacological Study of

Jul 15, 1995 - Phase I Clinical and Pharmacological Study of Suppression of Human Antimouse. Antibody ... V. V., D. B., H. W., G. H.¡,Laboratory Me...

1 downloads 3 Views 2MB Size

Recommend Documents

Mar 15, 2008 - nary function defined as a carbon monoxide diffusion capacity of at least 80% of predicted and a ... UV detection was accom plished using a ...

Mar 15, 2008 - cycle of therapy was 805/ul and the median platelet nadir was 48,000/ul. Other toxic .... This was achieved using a Waters model 510 pump and ...

control. Clinical Pharmacological Studies. The pharmacokinetic behavior of. IDR was examined using a HPLC method adapted from that of Peng. 2990. Research. ... Compounds were de tected by fluorescence, using excitation and emission wavelengths of. 47

Departments of Medicine [J. L, A. T. H.. W. D. B., C. J.. .... abbreviations used are: ..... ftn. QJ . ÖU. uÜ 60 i. 40. 5 et. 20 • "' •IO •121. 16)- •141. 131.

long-term venous access catheters has made prolonged infusion of vinblastine and ... 3The abbreviations used are: CVI, continuous vinblastine infusion; VLB«, steady-state serum ..... N. Engl. J. Med., 291: 127-133, 1974. 18. Ratain, M. J. ...

AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol. Cancer Ther. 2008;7(9):2955-66. 44.

(Milford,. MA) as well as a Spectroflow. 980 programmable fluorescence detector. (Kratos. Division, ...... E. M., Pajak, T. F., and Bateman,. J. R. Adriamycin given.

Departments of Pediatric Hematology/Oncology, State University of. New York Upstate Medical University, .... Downloaded from ..... Neuro-Oncology, 4: 102–108, 2002. 5. .... Bernstein, M. L. WR-2721 (amifostine) infusion in patients with Ew-.

Val and 5-methylbenzoic acid form the lateral chain. The cycled region ...... (M)/prednisone (P) in men with androgen independent prostate cancer. J Clin Oncol ...

(/')determined the human pharmacokinetics of the drug on a. 6-h infusion ..... dexamethasone, and/or aminophylline were required to treat the reactions.

POH was formulated in soft gelatin capsules con- .... Drug Formulation. ... phase I design. .... No significant problems with myelosuppression were seen. Grade 1 ...

Phase I and Clinical Pharmacology Study of Intravenous Flavone Acetic Acid. (NSC347512)1 .... tration was achieved by evaporation under nitrogen. A standard ...

Antisense Oligonucleotide ISIS 3521 Administered in Combination with 5-Fluorouracil and Leucovorin in Patients with. Advanced Cancer1. Sridhar Mani,2 ...

staurosporine family of agents, which have two indole nitrogens linked to a carbohydrate residue. Representatives from both of these subgroups have been the ...

to the antifolate drugs trimetrexate, metoprine, homofolate, and CB3717 in human lymphoma and osteosarcoma cells resistant to methotrexate. Cancer. Res.

infusion solutions are compatible with PVC i.v. infusion bags and are chemically stable ... two cycles of treatment. Disease assessments by any tech- ...... Click on "Request Permissions" which will take you to the Copyright Clearance Center's.

Jan 15, 1994 - Phase I and Pharmacological Study of the Novel Topoisomerase I Inhibitor .... to the aqueous insolubility of the closed-ring CPT lactone (1-7). ... O2CH 3. SN-38. Fig. 1. Structures of CPT-11 and SN-38. To date, phase I and II trials o

9-AC,3 9-nitrocamptothecin, topotecan, irinotecan, karenitecin, and DX-8951f ... of 12 weeks, adequate bone marrow reserve (defined as ab- solute neutrophil ...

them, to break down all of the components of the ECM, includ- ing the basement membrane (1). ... novel synthetic hydroxamic acid derivative (Fig. 1) able to .... (free base). 1913 ..... We wish to thank Drs. T. S. Ganesan and N. Dobbs (Imperial.

At the 560 mg/m2/day dose level, the mean percentage of .... patients with advanced solid malignancies; (b) determine the ... gational agents in the previous 4 weeks; (g) no nitrosoureas or ... local reactions were not considered in altering the incr

(254-S; NSC 37510ID) Administered by 5-Day Continuous Intravenous ..... macodynamics was calculated by the method of simple least squares of .... crease in total plasma platinum concentration between the early and later stages of drug administration.

anemia, and brief transaminasemia. One patient who received antibody alone had an apparent acute immune complex-mediated reaction. Ten of. 11 patients ...

C.P. Thakur, S. Narayan* & A. Ranjan* ..... editors. A hand book of tropical diseases, 6th ed. Calcutta: ... Thakur CP, Singh RK, Hassan SM, Kumar R , Narain S,.

Heinrich, M. C. SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase. Blood, 100: 2941–2949,. 2002. 8. O'Farrell ...